The average P/S ratio for HUMA's competitors is 22.54, providing a benchmark for relative valuation. Humacyte Inc Corp (HUMA) exhibits a P/S ratio of 31.51, which is 39.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.